EP1038178A1 - Methode diagnostique de detection de metalloprotease matricielle-9 et utilisation de ladite methode - Google Patents
Methode diagnostique de detection de metalloprotease matricielle-9 et utilisation de ladite methodeInfo
- Publication number
- EP1038178A1 EP1038178A1 EP99953097A EP99953097A EP1038178A1 EP 1038178 A1 EP1038178 A1 EP 1038178A1 EP 99953097 A EP99953097 A EP 99953097A EP 99953097 A EP99953097 A EP 99953097A EP 1038178 A1 EP1038178 A1 EP 1038178A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mmp
- antibody
- solid support
- pro
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 title claims abstract description 29
- 238000003556 assay Methods 0.000 title abstract description 37
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 title description 6
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims abstract description 26
- 239000012472 biological sample Substances 0.000 claims abstract description 24
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 239000003593 chromogenic compound Substances 0.000 claims description 4
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 abstract description 14
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 abstract description 6
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 abstract description 5
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 abstract description 5
- 238000011002 quantification Methods 0.000 abstract 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 26
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 26
- 239000000523 sample Substances 0.000 description 23
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 20
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 108010062466 Enzyme Precursors Proteins 0.000 description 12
- 102000010911 Enzyme Precursors Human genes 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 11
- 239000003085 diluting agent Substances 0.000 description 10
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 4
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- -1 wound healing Diseases 0.000 description 4
- 102000007299 Amphiregulin Human genes 0.000 description 3
- 108010033760 Amphiregulin Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000003312 immunocapture Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 108010026027 Hemopexin Proteins 0.000 description 2
- 102000013271 Hemopexin Human genes 0.000 description 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000002726 cyst fluid Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000054439 human MMP9 Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 238000007805 zymography Methods 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000669516 Bos taurus Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 description 1
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010088090 pro-matrix metalloproteinase 9 Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010067415 progelatinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102220047090 rs6152 Human genes 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000013579 wash concentrate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000034365 zymogen activation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Definitions
- the present invention relates to assay methods for quantitation of metalloproteinase 9 (MMP-9) in biological samples using immunocapture techniques.
- the assay is designed to quantify both free MMP-9 and MMP-9 complexed with the tissue inhibitor of metalloproteinase 9, TIMP-1.
- this invention relates to methods and techniques for specifically selecting and isolating an MMP-9 from a biological sample, followed by the measurement of the amount of MMP-9, by using an antibody.
- the assay method is useful in the diagnosis and prognosis of diseases and disorders relating to MMP-9, including cancer.
- ECM extracellular matrix
- the MMPs are members of a multigene family of metal-dependent enzymes. These proteases have been classified into four broad categories originally based on substrate specificity. These specific enzymes are the collagenases (MMP-1/EC3.4.24.7; MMP- 8/EC3.4.24.34;MMP-13), the gelatinases A(MMP-2/EC3.4.24.24) and B(MMP- 9/EC3.4.24.35), the stromelysins (MMP-3/EC3.4.24.17:MMP-10/EC3.4.24.22; MMP- 11/EC3.4.24.7) including a metalloelastase (MMP-12) and the membrane MMPs (MMP- 14).
- MMP-12 metalloelastase
- MMP- 14 membrane MMPs
- MMPs are a key component of a system of "balanced proteolysis" wherein a finely tuned equilibrium exists between the amount of active enzyme and its proteinase inhibitor(s).
- TIMPS tissue Inhibitor of MetalloProteinase
- Matrix metalloproteinase-9 (MMP-9; 92-kDa gelatinase B) is an important member of the MMP family involved in tumor invasion and metastasis. Woodhouse, et al. Cancer. 80 (Suppl. 8):1529-1537, 1997; Chambers, et al. J. Natl. Cancer Inst. 89:1260-1270, 1997; Coussens, et al. Chem. Biol. 3:895-904, 1996; Yu, et al. Drugs Aging. 11 :229- 244, 1997; Kohn, et al. Cancer Res. 55:1856-1862, 1995.
- MMP-9 is a collagenase with specificity for type IV collagen, which makes up the backbone of the basement membrane.
- the proteolytic degradation of the ECM is an important aspect of many physiological and pathological conditions associated with alterations in connective tissue proteins such as embryo implantation, morphogenesis, wound healing, ovulation, cell migration, tissue involution, angiogenesis, and tumor invasion. DeClerk, et al. Adv. Exp. Med. Biol. 425:89-97, 1997.
- MMP-9 is secreted from stimulated macrophages, neutrophils and transformed cells in a latent form.
- TIMPs tissue inhibitors of metalloproteinases
- the MMP-9 protein has four structural domains: an amino-terminal propeptide, a catalytic domain, a fibronectin type-II like domain within the catalytic domain and a hemopexin-like domain at the carboxyl-terminal.
- Massova et al. FASEB J. 12:1075- 1095, 1998. Cleavage of the propeptide results in zymogen activation.
- the catalytic domain contains two zinc ions and a calcium ion.
- MMP-9 incorporates three repeats homologous to the type-II module of fibronectin into the catalytic domain. This region is also known as the gelatin binding domain and is involved in binding to denatured collagen or gelatin. Murphy, et al. J. Biol.
- the hemopexin-like domain is highly conserved among MMPs and shows sequence similarity to the plasma protein, hemopexin.
- the hemopexin like domain has been shown to play a functional role in substrate binding and/or in interactions with the tissue inhibitors of metalloproteinases (TIMPs).
- TIMP-1 binds exclusively to the zymogen form of MMP-9 (Kd ⁇ 35 nM)
- TIMP-2 binds to the zymogen form of MMP-2 (Kd ⁇ 5 nM). Murphy, et al. Matrix Biol. 15:511-518, 1997.
- MMPs play an important role in normal and pathological process, including embryogenesis, wound healing, inflammation, arthritis and cancer, it would be desirable to have a highly specific and accurate assay to measure MMP levels in patient samples.
- the present invention employs an improved immunoassay that detects all forms of MMP-9 (both the form complexed with TIMP and the "free" uncomplexed form) in biological samples including human serum and plasma.
- the assay is preferably a capture assay using two antibodies to MMP-9 that do not compete with each other (i.e., bind to distinct epitopes). The epitopes that are bound to must be exposed in both the complexed MMP-9 as well as the free MMP-9.
- a detector MMP-9 antibody and a capture anti- MMP-9 antibody.
- serum pro-matrix metalloproteinase- 9 precursor of matrix metalloproteinase 9, pro-MMP-9, progelatinase B
- pro-MMP- 9/TIMP1 complex levels [pro-MMP-9 noncovalently bound to tissue inhibitor of metalloproteinases (TIMP-1)] are elevated in cancer patients.
- a monoclonal anti-MMP-9 antibody such as clone 6-6B (ORP product MMP9 (Ab-1), Cat #IMO9L) and a polyclonal antibody to MMP-9 which is available from BioDesign (Cat.# K90163C).
- clone 6-6B ORP product MMP9 (Ab-1), Cat #IMO9L)
- polyclonal antibody to MMP-9 which is available from BioDesign (Cat.# K90163C).
- the improved immunoassay of the present invention has excellent clinical utility. For example, ninety percent of cancer sera read above normal samples and most of the pro- MMP-9 in cancer sera is found to be complexed with TIMP-1.
- the present invention provides a method of determining the presence of an MMP-9 associated disorder, e.g., cancer, comprising the step of assaying a biological sample obtained from a patient for the presence of free MMP and MMP/TIMP complexes, such as MMP-9 and pro-MMP-9/TIMP-l complexes.
- MMP-9 above normal limits correlates with the presence of cancer.
- the measurement of the level of MMP-9 in a biological sample is useful in the diagnosis, prognosis, and treatment of cancer as well as monitoring of a patients response to therapy and staging of disease.
- the present inventors have detected pro-MMP-9 protein complexed with TIMP-1 and uncomplexed MMP-9 in human sera and plasma samples and cell culture supernatants. Specificity was demonstrated by immunoaffmity extraction (inhibition of assay signal) of pro-MMP-9 positive samples by a specific pro-MMP-9 antibody and a specific TIMP-1 antibody. For instance, an MMP-9 antibody, which is not a component of the ELISA, extracted the MMP-9 which leads to loss of signal in the assay (almost all the signal was lost), while the control antibody (e.g., a non MMP- 9) did not affect the signal of the MMP-9 positive samples (see Figure 3).
- TIMP-1 antibody extracted pro-MMP-9 activity detected by this immunoassay, but very little of the pro-MMP-9 activity detected by other traditional immunoassays which shows that the traditional assay detects mainly uncomplexed MMP-9 protein and therefore fails to accurately measure MMP-9 levels in patient samples. Addition of TIMP-1 and TIMP-2 recombinant proteins to both positive and negative samples does not change the level of MMP-9 detected.
- the present invention further provides a general method for the detection and quantitation of a MMP-9 in a biological fluid from a human.
- the method comprising the steps of:
- one antibody is polyclonal and the other is monoclonal.
- the amount of MMP-9 in the biological sample is determined from the amount of detectably labeled antibody bound to the solid support.
- the detectably labeled antibodies can be labeled with a detectable substance such as, for example, biotin, radioactive agents, chromophoric agents, enzymatic agents, chemiluminescent, fluorometric and haptenic.
- the method of the invention for measuring MMP levels in biological samples contemplates the use of a capture antibody, which can be a monoclonal, polyclonal recombinant or chimeric antibody, and a detectably labeled antibody, which can also be a monoclonal, polyclonal recombinant or chimeric antibody.
- the present invention further provides a kit useful for the detection of MMP-9 in a biological sample.
- This kit comprises antibodies which specifically bind MMP-9 to capture the MMP-9 present in the sample and a detectably labeled antibody which specifically binds MMP-9, such as pro-MMP-9, to quantify the amount of MMP-9.
- Figure 1 shows a standard curve: The mean signal of of each standard run in replicates of four in eight assays using two different lots of plates and two lots of detector antibody.
- Figure 2 shows the sensitivity of one embodiment of the assay of the present invention:
- the lower limit of detection (LLD) commonly used to define sensitivity, was measured by assaying four replicates of zero eight times using two different lots of plates and two different lots of detector antibody. The grand mean signal and pooled standard deviation of zero was calculated. The grand mean of each standard (run in replicates of four in the eight assays) was used for the standard curve ( Figure 1), and the response, mean signal of zero plus two standard deviations, read in dose from the standard curve is the LLD; that is, the smallest dose that is not zero with 95% confidence.
- LLD lower limit of detection
- Figure 3 shows the specificity of an assay of the present invention: Levels of MMP-9 detected by the ELISA after immunoaffinity extraction of MMP-9 positive samples (PMA treated HT1080 and HL-60 cells) with a MMP-9 antibody that is not used in the ELISA, a TIMP-1 antibody, a TIMP-2 antibody and a TIMP-3 antibody.
- FIGS 4A-4D show levels of MMP-9 detected by the MMP-9 ELISA of the present invention after 2-aminophenylmercuric acetate (APMA) treatment.
- APMA promotes the autocatalytic cleavage of the N-terminal prosequence of the latent 92-kDa enzyme to yield the active form of the enzyme.
- Analysis of the samples by zymography showed both cleavage of the proenzyme by APMA and a good correlation with the levels of the proenzyme determined with the MMP-9 ELISA.
- MMP-9 induction was used to generate positive samples such as treatment with 50 ng/ml amphiregulin (AR), 50 ng/ml epidermal growth factor (EGF), 1 ng/ml transforming growth factor beta (TGFb) and 25 ng/ml phorbol 12- myristate 13-acetate (PMA).
- AR amphiregulin
- EGF epidermal growth factor
- TGFb transforming growth factor beta
- PMA 25 ng/ml phorbol 12- myristate 13-acetate
- Normal human sera (NHS) containing moderate levels of MMP-9 were as treated with APMA and analyzed.
- FIG. 5 shows phorbol ester induced up-regulation of MMP-9 protein in HL-60 cells. It has been shown that the induction of MMP-9 gene expression is associated with macrophage differentiation. Xie, et al. J. Biol. Chem. 273:11576-11582, 1998. Phorbol 12-myristate 13-acetate (PMA) at all concentrations studied induced the synthesis of MMP-9 protein. This up regulation closely parallels the timing of PMA induced cell adhesion and spreading, a hallmark of macrophage differentiation.
- PMA Phorbol 12-myristate 13-acetate
- Figure 6 shows phorbol ester induced up-regulation of MMP-9 in HT1080.
- PMA has been shown to increase the expression of MMP-9 by HT1080 cells. Morodomi, et al. Biochem. J. 285: 603-611, 1992; Lim, et al. J. Cell. Physiol. 167:333-340, 1996.
- the MMP-9 ELISA of the present invention detects this increase in synthesis in a time dependent matter.
- Figures 7A and 7B show detection of MMP-9 in Human Sera and Plasma: Levels of MMP-9 detected by the assay of the present invention are significantly elevated in cancer sera samples compared to normal sera and plasma samples (left figure is the data on a logarithmic scale and the right is a linear scale). The following samples were assayed: normal human sera (NHS), normal human plasma (NHP), sera from cervical cancer (CV), breast cancer (BR) and prostate cancer (PT) patients.
- NHS normal human sera
- NHS normal human plasma
- CV cervical cancer
- BR breast cancer
- PT prostate cancer
- Figure 8 shows the clinical utility of the MMP-9 Immunoassay of the present invention.
- the assay has a 90% percent clinical sensitivity (ability to recognize affected individuals) at a 95 % clinical specificity (ability to recognize unaffected individuals).
- Figure 9 shows parallelism using the assay of the present invention: The study tested dilution-recovery often positive samples. The dilutions were run in the MMP-9 ELISA and the "found" doses were plotted against the "expected” doses to determine linearity of dilution. The slope is not significantly different from one and the intercept is not significantly different from zero.
- Ca Cancer
- NHS Normal Human Sera
- NHP Normal Human Plasma
- PMA Phorbol 12-myristate 13-acetate
- EGF Epidermal Growth Factor
- AR Amphiregulin
- Both EGF and AR
- A 2 x 10 6 cells/ml
- B 1.0 x 10 6 cells/ml.
- Figure 10 shows the precision of the assay of the present invention:
- the pooled coefficients of variation (according to the formula of Henry, R.J., Cannon, CD., and Winkleman, J.W., Clinical Chemistry, 1974 Harper and Row, New York, N.Y.) and between assay coefficients of variation are plotted against MMP-9 concentrations.
- the pooled data were collected from samples run eight times using two different lots of plates and two different lots of detector antibody in replicates of four on two separate occasions.
- the present invention provides an immunoassay, e.g., a "sandwich” enzyme immunoassay employing antibodies specific for both free and complexed MMP-9.
- the epitopes need to be exposed in both the free and complexed form.
- the detector antibody binds the pro-MMP-9 form.
- the antibody, specific for the human MMP-9 protein is immobilized onto surface of a solid phase support, e.g., an immunoassay plate, (other solid supports such as beads, tubes or magnetic particles can be used as well).
- a labeled e.g., biotinylated, detector antibody that is specific for pro-MMP-9 is added.
- the detector antibody can be simultaneously pipetted into the wells and allowed to incubate for a period of time (e.g., two hours), during which any MMP-9 present binds to both the capture and detecting antibodies. Unbound material is washed away and, if the detector antibody is biotinylated, horseradish peroxidase-conjugated streptavidin is added, which binds to the detector antibody.
- the horseradish peroxidase catalyzes the conversion of a chromogenic substrate (i.e., tetramethylbenzidine) from a colorless solution to a colored solution, the intensity of which is proportional to the amount of pro- MMP-9 protein in the sample.
- the colored reaction product is quantified using a spectrophotometer.
- the streptavidin-biotin- horseradish peroxidase labeled immunologically responsive substance such as radioactive agents, chemiluminescence agents, bioluminescence agents, fluorescence agents, or other chromophoric agents.
- the detector antibody can be directly labeled or labeled indirectly with other molecules in place of biotin.
- Quantitation is achieved by the construction of a standard curve using known concentrations of, e.g., the pro-MMP-9. By comparing the signal obtain from a sample containing an unknown amount of a pro-MMP-9 with that obtained from a known concentration of a pro-MMP-9, the concentration of the MMP-9 in the sample can be determined.
- an ELISA uses two antibodies that bind to nonoverlapping epitopes on the same antigen and may utilize either two antibodies that recognize discrete sites on an antigen or one batch of affinity-purified polyclonal antibodies.
- the assay of the present invention can employ a capture antibody specific for both free and complexed MMP-9 and a non-antibody system for detecting the captured protein.
- a capture antibody specific for both free and complexed MMP-9 and a non-antibody system for detecting the captured protein.
- Antibodies which specifically bind MMP-9 can include human or animal (e.g., rabbit, mouse, rat, etc.) polyclonal or monoclonal or recombinant or chimeric antibodies. Methods used to prepare and purify polyclonal, monoclonal, recombinant and chimeric antibodies are known in the art.
- anti-MMP-9 antibodies are also available commercially.
- anti-MMP-9 antibodies include:
- the detectably labeled antibody can be labeled using any of a variety of labels and methods of labeling known in the art.
- types of labels encompassed by the present invention include, but are not limited to, radioisotopic labels (e.g., 125 1, 131 1, 35 S, 14 C, etc.), non-radioactive isotopic labels 55 Mn, 56 Fe, etc.), fluorescent labels (e.g., a fluorescein label, an isothiocyanate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an o-phthaldehyde label, a fluorescamine label, etc.), chemiluminescent labels, enzyme labels (e.g., alkaline phosphatase, horse radish peroxidase, etc.), protein labels, etc.
- radioisotopic labels e.g., 125 1, 131 1, 35 S, 14 C, etc.
- Biological samples include body fluids, for example, plasma, serum, saliva, urine, lung lavage fluid, cyst fluid, etc., and tissue extracts wherein the tissue pieces are removed and separated from the liquid extract.
- the pro-MMP-9 present in a biological sample for example, plasma, serum, saliva, urine, lung lavage fluid, cyst fluid, tissue extract, etc.
- a biological sample for example, plasma, serum, saliva, urine, lung lavage fluid, cyst fluid, tissue extract, etc.
- the immunocapture assay can be performed in solution phase or on solid support as is well known in the art.
- the anti-pro-MMP-9 antibodies are affixed onto a solid support by any stable interaction known to the art such as hydrophobic, electrostatic or covalent interaction.
- solid supports are microtiter plates, magnetic particles, beads, sheets, membranes, chromatography resins, e.g., Sepharose, etc.
- multiwell microtiter plates or nitrocellulose membranes are used, so that when the pro-MMP-9 is captured by the antibodies, the resultant immunological complex is immobilized and easily isolated, e.g., by rinsing away non-binding material remaining in the biological sample.
- the method of this invention has utility in screening biological samples to detect malignancy through the measurement of high levels of MMP9 and pro-MMP-9, in the sample material.
- This invention also contemplates the preparation of a kit useful for the detection of pro-MMP-9 in a biological sample.
- a kit useful for the detection of pro-MMP-9 in a biological sample.
- Such a kit comprises anti-pro-MMP-9 antibodies, adsorbed onto a solid support, preferably a microtiter plate having from approximately four to approximately ninety-six wells and a second anti-pro-MMP-9 antibody conjugated to a label; and, where necessary, a means for measuring said label.
- the MMP-9 ELISA disclosed in this example is a "sandwich" enzyme immunoassay employing a mouse monoclonal antibody and a sheep polyclonal antibody.
- An antibody, specific for the human MMP-9 protein, has been immobilized onto the surface of microtiter wells using standard techniques.
- the sample to be assayed and biotinylated detector monoclonal antibody are pipetted into the wells and allowed to incubate for two hours, during which time any MMP-9 present binds to the capture and detecting antibodies. Unbound material is washed away and horseradish peroxidase-conjugated streptavidin is added, which binds to the detector antibody.
- the detector antibody is anti-MMP-9 mouse monoclonal antibody clone 6-6B (ORP product MMP9 (Ab-1), Cat # IM09L).
- the capture antibody is an anti-MMP-9 polyclonal raised in sheep and obtained from BioDesign of Kennebunk, Maine (Cat # K90163C).
- the horseradish peroxidase catalyzes the conversion of the chromogenic substrate tetra-methylbenzidine (TMB) from a colorless solution to a blue solution (or yellow after the addition of stopping reagent), the intensity of which is proportional to the amount of MMP-9 protein in the sample.
- TMB chromogenic substrate tetra-methylbenzidine
- the colored reaction product is quantified using a spectrophotometer.
- Quantitation is achieved by the construction of a standard curve using known concentrations of MMP-9. By comparing the absorbance obtained from a sample containing an unknown amount of MMP-9 with that obtained from the standards, the concentration of MMP-9 in the sample can be determined.
- This example discloses the use of one embodiment of the assay of the present invention.
- Standards should be assayed in duplicate. A standard curve must be performed on the same plate and at the same time as the samples.
- the MMP-9 ELISA provides sufficient reagents to ran two sets of standard curves, and 41 samples (if assayed in duplicate all at once using one standard curve), or 34 samples (if assayed on two separate occasions using two standard curves).
- MMP-9 STANDARD two vials containing lyophilized MMP-9 protein calibrated to recombinant MMP-9 protein. Reconstituted standards should be discarded after one use.
- DETECTOR ANTIBODY Biotinylated monoclonal anti-human MMP-9 antibody.
- PLATE SEALERS To cover plates during incubations. Sample Preparation For suspension cells: Pellet by centrifugation (1000 x g for 10 minutes, 4 °C) and remove supernatant for testing. Samples may be stored at -20 °C.
- tissue culture media remove tissue culture media, centrifuge tissue culture media (1000 x g for 10 minutes), and remove supernatant for testing. Samples may be store at -20 °C.
- Samples found to contain greater than 20 ng/ml MMP-9 must be diluted with Sample Diluent (provided), so that the MMP-9 concentration falls within the range spanned by the standard curve, and assayed again.
- the MMP-9 ELISA is provided with removable strips of wells so the assay can be carried out on two separate occasions. Since conditions may vary, a standard curve MUST be determined each time the assay is performed. Standards should be assayed in duplicate. Disposable pipette tips and reagent troughs should be used for all transfers to avoid cross-contamination of reagents or samples.
- FLOOD ENTIRE PLATE WITH dH 2 O Remove contents of wells by inverting over sink and tapping on paper towels.
- the MMP-9 concentration must be multiplied by the dilution factor (ie., if the sample was diluted five-fold, then the MMP-9 value obtained from the standard curve must be multiplied by five).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention met en oeuvre une analyse immunologique permettant de détecter toutes les formes de MMP-9 ( à la fois la forme complexée avec TIMP et la forme 'libre' non complexée) dans des prélèvements biologiques du type sérum et plasma. La mise en oeuvre de cette méthode immunologique permet un niveau de détection et de quantification bien supérieur aux analyses précédentes. Cette méthode est de préférence un dosage en captivité mettant en oeuvre deux anticorps dirigés contre les MMP-9 qui ne se font pas concurrence (c'est à dire qu'ils se lient à des épitopes distincts). Les épitopes engagés dans une liaison doivent être exposés à la fois dans la MMP-9 complexée et dans la MMP-9 libre.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16852698A | 1998-10-08 | 1998-10-08 | |
US168526 | 1998-10-08 | ||
PCT/US1999/023443 WO2000020860A1 (fr) | 1998-10-08 | 1999-10-07 | Methode diagnostique de detection de metalloprotease matricielle-9 et utilisation de ladite methode |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1038178A1 true EP1038178A1 (fr) | 2000-09-27 |
Family
ID=22611856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99953097A Withdrawn EP1038178A1 (fr) | 1998-10-08 | 1999-10-07 | Methode diagnostique de detection de metalloprotease matricielle-9 et utilisation de ladite methode |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1038178A1 (fr) |
JP (1) | JP2002526772A (fr) |
AU (1) | AU6511199A (fr) |
WO (1) | WO2000020860A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7374886B2 (en) | 1999-04-09 | 2008-05-20 | Rigshospitalet | Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer |
AU771309B2 (en) | 1999-04-09 | 2004-03-18 | Rigshospitalet | Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker |
FI990888A0 (fi) * | 1999-04-20 | 1999-04-20 | Medix Biochemica Ab Oy | Menetelmä ja testikittejä respiratorisen alueen tulehduksen läsnäolon ja vaikeusasteen arvioimiseksi |
US7041787B2 (en) | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
US6906036B2 (en) | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
US7186693B2 (en) | 2001-08-16 | 2007-03-06 | Kimberly - Clark Worldwide, Inc. | Metalloproteinase inhibitors for wound healing |
US7094754B2 (en) | 2001-08-16 | 2006-08-22 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
US7071164B2 (en) | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
US7148194B2 (en) | 2002-12-30 | 2006-12-12 | Kimberly-Clark Worldwide, Inc. | Method to increase fibronectin |
US7189700B2 (en) | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
WO2006007869A1 (fr) * | 2004-07-23 | 2006-01-26 | Centre De Recherche Public De La Sante | Surveillance d'une insuffisance cardiaque |
DK2185175T3 (da) * | 2007-08-15 | 2013-05-13 | Yeda Res & Dev | MMP-9-regulatorer og anvendelser deraf |
CN106525793B (zh) * | 2016-10-31 | 2019-06-21 | 陕西脉元生物科技有限公司 | 一种利用荧光酶谱印迹技术检测mmp-9的方法 |
CN114252609A (zh) * | 2021-12-23 | 2022-03-29 | 武汉生之源生物科技股份有限公司 | 一种基质金属蛋白酶-9的检测试剂盒及其检测方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324634A (en) * | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
DE69333167T2 (de) * | 1992-10-29 | 2004-06-09 | Bayer Corp. | Diagnostischer test spezifisch für die latente matrix metalloproteinase no. 9 |
US5641636A (en) * | 1994-05-20 | 1997-06-24 | University Of Pennsylvania | Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity |
AU6012696A (en) * | 1995-06-14 | 1997-01-15 | Aberdeen University | Prognostic and therapeutic system for cancer |
GB9607287D0 (en) * | 1996-04-09 | 1996-06-12 | British Biotech Pharm | Diagnosis method |
-
1999
- 1999-10-07 AU AU65111/99A patent/AU6511199A/en not_active Abandoned
- 1999-10-07 JP JP2000574927A patent/JP2002526772A/ja active Pending
- 1999-10-07 WO PCT/US1999/023443 patent/WO2000020860A1/fr not_active Application Discontinuation
- 1999-10-07 EP EP99953097A patent/EP1038178A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0020860A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002526772A (ja) | 2002-08-20 |
WO2000020860A1 (fr) | 2000-04-13 |
AU6511199A (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5324634A (en) | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer | |
US7153660B2 (en) | Non-invasive enzyme screen for tissue remodelling-associated conditions | |
Hanemaaijer et al. | A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels | |
Baker et al. | Serum metalloproteinases and their inhibitors: markers for malignant potential | |
WO2000020860A1 (fr) | Methode diagnostique de detection de metalloprotease matricielle-9 et utilisation de ladite methode | |
Margulies et al. | Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. | |
US20020106708A1 (en) | Assays reagents and kits for detecting or determining the concentration of analytes | |
CN106950382A (zh) | 基质金属蛋白酶‑3测定试剂及其制备方法 | |
AU2002211697A1 (en) | Non-invasive enzyme screen for tissue remodelling-associated conditions | |
Zucker et al. | Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma | |
CA2252648C (fr) | Depistage d'enzymes noninvasif dans les etats associes au remodelage tissulaire | |
US20090117604A1 (en) | Proteolytic enzymes in urine as diagnostic parameters in diseases involving matrix remodelling | |
Cheng et al. | Advances in assays of matrix metalloproteinases (MMPs) and their inhibitors | |
CA2500232A1 (fr) | Methode de detection, de depistage et/ou de surveillance d'un cancer chez un individu | |
Eisenberg et al. | Concordance of creatine kinase-MB activity and mass. | |
US20040029200A1 (en) | Method and kits for the detection of renal cell carcinoma in a biological fluid of a patient | |
CA2693451A1 (fr) | Procede combine et coffret pour la mesure sequentielle de (1) la fraction a activite enzymatique et (2) la quantite totale d'une enzyme | |
Janeiro et al. | Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays | |
US5601988A (en) | Immunocapture assay for cancer procoagulant antibody complex in biological samples | |
US20060154245A1 (en) | Method for detecting, screening and/or montoring a cancer in individual | |
Matsumoto et al. | ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen—assay-specific for complexed prostate-specific antigen | |
EP0574599A1 (fr) | Procédé pour la détection de cathépsine G et alpha-1-antichymotrypsine complexe | |
WO2019046288A1 (fr) | Compositions et dosages multiplexes pour caractériser des protéases actives et leurs inhibiteurs | |
US20060105400A1 (en) | Elisa kits for detecting collagenase 3 as a proenzyme and in an activated form in body fluids and cell culture supernatants | |
WO1995000847A1 (fr) | Dosage immunologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000628 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020502 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): CH DE GB LI |